Pravastatin for Hyperlipidaemia in HIV.
HIV Infections, Lipid Metabolism, Glucose Metabolism
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Hyperlipidaemia, Lipid metabolism, Glucose metabolism, HMG CoA reductase inhibitors, Lipodystrophy, Cardiovascular disease, Treatment Experienced, HIV
Eligibility Criteria
Inclusion Criteria: Provide written informed consent to participate in the trial HIV-1 sero-positive Male/female >18 years age Currently receiving HIV protease inhibitor therapy for > 12 weeks and unlikely to require change in existing regimen during the 16 week study period Fasting cholesterol > 6.5 mmol/L (mean of 2 samples collected > 3 days apart) Exclusion Criteria: Any condition which may interfere with ability to comply with study Gastrointestinal disorder which may affect drug absorption Hypertension or congestive cardiac failure Lactic acidemia (serum lactate level >2.2 mmol/L) Any serious medical condition which may compromise the patient's safety, including pancreatitis or hepatitis within past 6 months Active AIDS defining conditions Concurrent therapy with any other lipid lowering agents, oral hypoglycaemics, anabolic steroids or insulin
Sites / Locations
- St. Vincents Hospital